Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Completed · Early Phase 1

Conditions studied: Multiple Myeloma

In brief

Eltrombopag may improve the cell collection available for Autologous Stem Cell Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and reduce the number of times blood needs to be collected. This study will also determine the highest dose of Eltrombopag that can be used without causing serious side effects.

Key facts

Study ID

NCT01286675

Run by

Dana-Farber Cancer Institute

People needed

19

Starts

2011-03-01

Expected to finish

2018-12-01

Last updated by the study team

2019-03-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Multiple myeloma
• Stable or responsive disease after at least 2 cycles of conventional chemotherapy
• Slated to undergo autologous peripheral blood stem cell transplant
• Normal organ and marrow function

You may not qualify if…

• Myocardial infarction within 6 months of treatment
• Receiving other study agents
• Pregnant or breastfeeding
• Uncontrolled intercurrent illness
• Evidence of active or recent history of thromboembolic disease
• Previous history of primary platelet disorder or bleeding disorder
• History of a different malignancy unless disease free for at least 5 years

Where it is running

• Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.